These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 21525763)

  • 1. Pathophysiological similarities and synergisms in alcoholic and non-alcoholic steatohepatitis.
    Hellerbrand C
    Dig Dis; 2010; 28(6):783-91. PubMed ID: 21525763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
    Mahli A; Hellerbrand C
    Dig Dis; 2016; 34 Suppl 1():32-9. PubMed ID: 27548267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
    Johnston MP; Patel J; Byrne CD
    Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis].
    Wiegand J; Mössner J; Tillmann HL
    Internist (Berl); 2007 Feb; 48(2):154-63. PubMed ID: 17226007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome.
    Dietrich P; Hellerbrand C
    Best Pract Res Clin Gastroenterol; 2014 Aug; 28(4):637-53. PubMed ID: 25194181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obesity and fatty liver are 'grease' for the machinery of hepatic fibrosis.
    Bosserhoff A; Hellerbrand C
    Dig Dis; 2011; 29(4):377-83. PubMed ID: 21894008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium.
    Purohit V; Russo D; Coates PM
    Alcohol; 2004 Aug; 34(1):3-8. PubMed ID: 15670659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coffee Intake and Liver Steatosis: A Population Study in a Mediterranean Area.
    Veronese N; Notarnicola M; Cisternino AM; Reddavide R; Inguaggiato R; Guerra V; Rotolo O; Zinzi I; Leandro G; Correale M; Tutino V; Misciagna G; Osella AR; Bonfiglio C; Giannelli G; Caruso MG;
    Nutrients; 2018 Jan; 10(1):. PubMed ID: 29342916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Non-alcoholic steatohepatitis - from NAFLD to MAFLD].
    Balmer ML; Dufour JF
    Ther Umsch; 2011 Apr; 68(4):183-8. PubMed ID: 21452138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both alcoholic and non-alcoholic steatohepatitis association with cardiovascular risk and liver fibrosis.
    Sánchez-Jiménez BA; Brizuela-Alcántara D; Ramos-Ostos MH; Alva-López LF; Uribe-Esquivel M; Chávez-Tapia NC
    Alcohol; 2018 Jun; 69():63-67. PubMed ID: 29660603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease and hepatitis C infection.
    Bondini S; Younossi ZM
    Minerva Gastroenterol Dietol; 2006 Jun; 52(2):135-43. PubMed ID: 16557185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-alcoholic fatty liver disease.
    Leclercq I
    Bull Mem Acad R Med Belg; 2010; 165(3-4):147-55; discussion 155-8. PubMed ID: 21166266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental models of metabolic and alcoholic fatty liver disease.
    Buyco DG; Martin J; Jeon S; Hooks R; Lin C; Carr R
    World J Gastroenterol; 2021 Jan; 27(1):1-18. PubMed ID: 33505147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis.
    Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Krag A; Karsdal MA; Nielsen MJ; Brockbank S; Cruwys S
    Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G410-G418. PubMed ID: 31905026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease versus Alcohol-related Liver Disease: Is it Really so Different?
    Craciun A; Lackner C; Cortez-Pinto H
    Curr Pharm Des; 2020; 26(10):1093-1109. PubMed ID: 31969088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease.
    Souza MR; Diniz Mde F; Medeiros-Filho JE; Araújo MS
    Arq Gastroenterol; 2012; 49(1):89-96. PubMed ID: 22481692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and diagnosis of NAFLD/NASH.
    Hashimoto E; Taniai M; Tokushige K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of diet and nutritional management in non-alcoholic fatty liver disease.
    Fan JG; Cao HX
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():81-7. PubMed ID: 24251710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty Liver Disease-Alcoholic and Non-Alcoholic: Similar but Different.
    Malnick SDH; Alin P; Somin M; Neuman MG
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microcirculatory disturbances and cellular changes during progression of hepatic steatosis to liver tumors.
    Liebig M; Hassanzada A; Kämmerling M; Genz B; Vollmar B; Abshagen K
    Exp Biol Med (Maywood); 2018 Jan; 243(1):1-12. PubMed ID: 29065724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.